Skip to content
Buy This GLP
← Research
Safety

Compounded GLP-1 Guidance: What One Health-System Survey Found

In one health system, 50 of 98 respondents who answered the question knew about the ADA statement. The survey also measured confidence in safety and affordability.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
One health system · December 2025Invitations523Responses submitted125 (23.9%)Eligible responses analyzed99

In a December 2025 survey at one U.S. health system, 50 of 98 people who answered an awareness question (51%) said they knew about an American Diabetes Association statement on compounded GLP-1 medicines. The statement was approved in 2024 and published in the February 2025 issue of Diabetes Care[1] [2].

Who answered the survey?

Our compounded semaglutide safety guide covers what regulators and studies say about the products. This survey asked what health professionals knew and how they used them. Researchers sent a 14-item survey to 523 people across sites in one health system. They received 125 replies (23.9%) and analyzed 99 that met their criteria, including 53 clinicians and 46 pharmacists. Some respondents skipped questions, so each result uses the number who answered that item [1].

What respondents said about safety and access

Low confidence in comparable safety was reported by 71 of 95 respondents (74.7%). At the same time, 65 of 94 (69.1%) expressed confidence that compounded products were more affordable than commercial products. Of the 91 people who answered the practice question, 52 (57.1%) said they had not incorporated the products into their practice [1].

What the FDA and ADA say

The FDA advises using compounded drugs only when an approved drug cannot meet the patient’s medical needs. Compounded drugs do not undergo FDA premarket review for safety, effectiveness or quality [3].

The ADA statement recommends against using non-FDA-approved compounded GLP-1 products because of concerns about safety, quality and effectiveness[2]. If you have questions about a prescription, ask your clinician and pharmacist which product you would receive and why it was selected.

Frequently asked

How many respondents knew about the ADA statement?
Fifty of the 98 people who answered the awareness question said they knew about the statement. The survey analyzed 99 eligible responses overall.
Did the survey assess whether compounded products were safe?
It asked about respondents’ confidence in safety and other aspects of these medicines. Researchers did not test products or measure patient outcomes.

Sources

  1. [1] Umbreit A, Neverman K, Kosloski Tarpenning K, et al. (2026). Assessing Awareness, Confidence and Utilization of Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists Among Healthcare Clinicians and Pharmacists: A Comprehensive Survey Study Journal of Primary Care & Community Health. PMID 42670579
  2. [2] Neumiller JJ, Bajaj M, Bannuru RR, et al. (2025). Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association Diabetes Care. Source
  3. [3] U.S. Food and Drug Administration (2026). FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss U.S. Food and Drug Administration. Source

More in Safety